November 27, 2024
The Patent Trial and Appeal Board has found Neurocrine Biosciences Inc. was able to show that all the claims in a patent owned by biotechnology company Spruce Biosciences Inc. relating to the treatment of a hormonal disorder were invalid.
December 05, 2023
The Patent Trial and Appeal Board has agreed to look into whether various claims in a pair of patents owned by a biotechnology maker are invalid, the latest event in a larger intellectual property fight over a treatment for a hormonal disorder.
August 04, 2023
The director of the U.S. Patent and Trademark Office on Friday reversed a Patent Trial and Appeal Board decision that refused to reassess a biotechnology maker's patent related to the treatment of a hormonal disorder.
July 25, 2023
The director of the U.S. Patent and Trademark Office has agreed to review a Patent Trial and Appeal Board decision that refused to reassess a biotechnology maker's patent related to the treatment of a hormonal disorder.